Skip to main
ORGO
ORGO logo

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc., a regenerative medicine company, has demonstrated solid operational results, which are expected to enhance its valuation amidst mixed market dynamics related to reimbursement changes. For CY2026, the finalized reimbursement rate for their products has seen a slight increase, suggesting potential for improved financial performance and operating profit as the company capitalizes on a consolidating market. The company's extensive product portfolio and underpenetrated market opportunity present a favorable growth trajectory, positioning Organogenesis for future gains.

Bears say

Organogenesis Holdings Inc faces a negative outlook primarily due to anticipated challenges in revenue growth stemming from lower-than-expected performance of its PuraPly product line and pricing pressures on amniotic products under Medicare Part B. Additionally, the company may struggle with competitive pressures as rivals potentially integrate more efficiently and navigate regulatory hurdles, resulting in constrained market share gains. Financially, the prospect of reduced sales forces may lead to decreased commissions and a subsequent impact on the company's profitability, exacerbated by increased R&D expenditures and extended timelines for regulatory clearances for new product initiatives.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.